According to filings with the U.S. Securities and Exchange Commission, Artelo Biosciences is raising up to $50,500,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Artelo Biosciences
Artelo Biosciences is a clinical stage company using cutting-edge science to improve patient care. We were founded on the promise of therapeutic development based on lipid-signaling modification. Our mission is to alter the course of treatment for those with a diagnosis of cancer and other serious conditions.

To learn more about Artelo Biosciences, visit https://artelobio.com/
Artelo Biosciences Linkedin Page: https://www.linkedin.com/company/artelo-biosciences-inc/

Contact:
Gregory Gorgas, President and Chief Executive Officer
858-925-7049
https://www.linkedin.com/in/gorgas/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.